Beaker
Beaker.com
Biogen CEO chases the holy grail of Alzheimers
Jeffrey Clark - Posted: 4/29/2015
At the World Medical Innovation Forum in Boston, Biogen CEO George Scangos discusses significant, yet early stage progress in a clinical trial for Alzheimers treatments. Scangos shared that his company would likely need to invest around $2.5 billion [...]
End of a run? Biotechnology stock, index drag down markets
Jeffrey Clark - Posted: 4/27/2015
CNBC pundits explore the recent pullback in biotechnology stocks, similar to a similar retrenchment in the spring of 2014. Those stocks down more than 10% today: Insys, Regulus, ImmunoGen, Akorn, and Aerie Pharmaceuticals. Celladon crashed by more th[...]
WSJ: Drug companies jacking prices to pay for deals
Jeffrey Clark - Posted: 4/27/2015
The Wall Street Journal has a strong article outlining one strategy pharmaceutical companies are using to fund this ongoing wave of mergers and acquisitions.  It seems that cost-savings and efficiency are the not the only financial factors when justi[...]
Mylan and Teva: Is bigger really better?
Jeffrey Clark - Posted: 4/22/2015
Mylan Labs was not overwhelmed thrilled by the unsolicited $40B bid from Teva Pharmaceuticals. And, in this instance (like many recent others), investors see a fit where the actual participating companies do not. With respect to Teva and Mylan, there[...]
NASDAQ CEO: The Golden Age of Biotech
Jeffrey Clark - Posted: 4/20/2015
Nasdaq CEO Robert Greifeld shares his views on recent trading activity in what he calls the golden age of biotechnology.
Aduro IPO skyrockets on high valuations
Jeffrey Clark - Posted: 4/16/2015
Aduro is a clinical-stage cancer immunotherapy company with three products currently in human trials. This week on CNBC, CEO Stephen Isaacs shares his opinion on cancer research, recent company valuations, selling Aduros pipeline to Novartis and J&J,[...]
Robots, robots everywhere across the life sciences
Jeffrey Clark - Posted: 4/15/2015
Robots arent new to the life sciences industry. Intuitive Surgical launched the trend 15 years ago with its da Vinci Surgical System. Since then, the system has conducted more than 20,000 surgeries and has paved the way for robotic advancements in he[...]
Inovia CEO talks large grant, potential for Ebola vaccine
Jeffrey Clark - Posted: 4/14/2015
Inovio Pharmaceuticals CEO Dr. Joseph Kim discusses how the companys $45 million Ebola grant will impact the development of drugs for both the prevention and treatment of the disease.
Biotechnology companies mature, start paying dividends
Jeffrey Clark - Posted: 4/6/2015
It seems like just yesterday, when the biotechnology industry was in its infancy, led by names like Amgen, Chiron and Immunex. Fast forward what seems like an instant, and the industry is all grown up. New names have emerged with Biogen, Celgene, Gil[...]
Investing in life sciences?
Jeffrey Clark - Posted: 3/31/2015
CNBC contributor Barbara Ryan of Clermont Partners discusses investing in life sciences.
Sanofi chairman talks deals, but not new CEO
Jeffrey Clark - Posted: 3/30/2015
According to its Chairman Serge Weinger in an interview with French newspaper Los Echos, Sanofi  has examined acquisitions opportunities but does not view deal-making as indispensable to its future. We looked at potential deals but found the asking p[...]
WSJ offers backroom perspective of Allergan vs. Valeant saga
Jeffrey Clark - Posted: 3/26/2015
The Wall Street Journal has published an article entitled Inside the Allergan Battle, a detailed insiders synopsis of the chess game between Allergan, Valeant, Pershing Square and ultimately Actavis, that led to last years biggest corporate acquisiti[...]
Edwards CEO Mussallem addresses Senate
Jeffrey Clark - Posted: 3/25/2015
Advamed went to the Senate yesterday to represent the life sciences industry during a hearing to the Mike Mussallem, Chairman and CEO of Edwards Lifesciences, represented AdvaMed and the interests of the industry itself. Mussallems comments can be fo[...]
Biomarin flying high on strong pipeline
Jeffrey Clark - Posted: 3/24/2015
BioMarin Pharmaceuticals CEO Jean-Jacques Bienaime discusses his companys recent high-flying stock performance and new drugs to treat rare diseases. Biomarin stock is up 67% over the past year, mostly on the promise of its pipeline which includes eig[...]
Novartis wins first FDA approval for biosimilar, to compete with Amgen
Jeffrey Clark - Posted: 3/20/2015
Novartis won FDA approval for its application to market its Zarxio as a biosimilar of Amgens Neupogen. While earlier biosimilars had been approved overseas, this is the first such drug approved by the agency. However, the FDA also stated that the dru[...]
Actavis acquires, becomes the new Allergan
Jeffrey Clark - Posted: 3/18/2015
Actavis has closed it deal to acquire Allergan for $70 Billion.   Just let that sink in for a bit Actavis is now officially part of Big Pharma, as one of the largest 10 pharmaceutical companies in the world. Allergan, which was rumored to be for sale[...]
ReWalk returns post-IPO with plans for growth
Jeffrey Clark - Posted: 3/17/2015
We have covered the growth and PR popularity of ReWalk Robotics in the past.  Late last week, the companys CEO Larry Jasinski, discussed the companys forecast for its ReWalk devices.
Landmark GSK, Novartis asset swap almost complete
Jeffrey Clark - Posted: 3/9/2015
Neither GlaxoSmithKline or Novartis has had an appetite for redefining megamergers in the past few years.   Instead, they have now accomplished the next best thing, swapping assets to reset their strategy and fuel growth for under their existing stru[...]
Boston Scientific, JnJ announce deals
Jeffrey Clark - Posted: 3/4/2015
Perhaps feeling left out of the wave of M&A activity across the pharmaceutical industry, two medical device giants both announced acquisitions this week. Boston Scientific said it will acquire Endos American Medical Systems urology portfolio for up t[...]
Celgene CEO talks pace of change for the future
Jeffrey Clark - Posted: 3/2/2015
Robert Hugin, Celgene Chairman & CEO, discusses his companys $90B market cap, the companys pipeline, and breakthrough treatments for cancer and other diseases. His insight into the pace of change in life sciences and his call to action for the coming[...]
Valeant CEO on CNBC talking Salix deal
Jeffrey Clark - Posted: 2/26/2015
Remember when Lilly CEO John Lechleiter caught so much heat for appearing on CNBC almost every week of the calendar?  Well, Valeant CEO Mike Pearson is making a run at the title. He appeared (on set, of course) with CNBC this week to review his compa[...]
Female Viagra resubmitted to FDA
Jeffrey Clark - Posted: 2/25/2015
Sprout Pharmaceuticals is again seeking FDA approval through a resubmission of its application to market its once-daily non-hormonal pill flibanserin for use in premenopausal women with hypoactive sexual desire disorder. The drug has a fascinating hi[...]
Valeant to pay $14.5B for Salix, another bidder?
Jeffrey Clark - Posted: 2/23/2015
Valeant and Salix both had a relatively horrible year in 2014. Perhaps, they will do better together in 2015. Last year, Valeant spent months trying to acquire Allergan and lost in the end to Actavis. Salix, meanwhile, suffered through severe wholesa[...]
Actavis to adopt Allergan name, poised for growth
Jeffrey Clark - Posted: 2/18/2015
Actavis CEO Brent Saunders briefed CNBC on Wednesday on details regarding the merger with Allergan, including the surprising news that the combined company will adopt the Allergan corporate name. According to Saunders: The acquisition is on track to [...]
John Oliver skewers Big Pharma on Last Week Tonight
Jeffrey Clark - Posted: 2/16/2015
John Oliver, formerly a correspondent with Comedy Centrals The Daily Show, now hosts his own program called Last Week Tonight on HBO. This past weekend, he roasted the global pharmaceutical industry in a segment which is both educational and well, fu[...]
 
 Beaker.com
Biogen CEO chases the hol[...]
At the World Medical Innovation Forum in Boston, Biogen CEO George Scangos discusses significant, ye[...]
End of a run? Biotechnolo[...]
CNBC pundits explore the recent pullback in biotechnology stocks, similar to a similar retrenchment [...]
Mylan and Teva: Is bigger[...]
Mylan Labs was not overwhelmed thrilled by the unsolicited $40B bid from Teva Pharmaceuticals. And, [...]
NASDAQ CEO: “The Golden A[...]
Nasdaq CEO Robert Greifeld shares his views on recent trading activity in what he calls “the golden [...]
Aduro IPO skyrockets on h[...]
Aduro is a clinical-stage cancer immunotherapy company with three products currently in human trials[...]